**Strong 2026 IPO momentum, fueled by AI-driven listings and resilient equity markets, has produced 251 U.S. IPOs year-to-date through early October, including recent pricings such as Accelevation and ADARx Pharmaceuticals.** Higher Treasury yields and selective investor demand have prompted some delays, notably Oura’s postponement, yet smaller and mid-sized deals continue to clear alongside high-profile candidates like Anthropic, which remains slated for potential November marketing. Fed policy, with the September rate hike and elevated long-term yields, has raised discount rates and tempered valuations, but robust earnings growth and AI capital expenditure sustain risk appetite. Multiple international and U.S. listings are already scheduled for the first half of October, reinforcing near-term activity before year-end.